CoChat

Does androgen‐deprivation therapy accelerate the development of frailty in older men with prostate cancer?: A conceptual review

Open access
Bylow, Kathryn, Mohile, Supriya G., Stadler, Walter M., Dale, William · 2007 · Cancer
Cited by 131

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

The majority of men with prostate cancer are aged ≥65 years. Men, as they age, are more likely to suffer from impaired physical function. The standard treatment for recurrent prostate cancer is androgen‐deprivation therapy (ADT). Well‐established toxicities from ADT include lean weight loss or sarcopenia, muscle weakness, fatigue, and reduced activity levels. Frailty is a term from geriatrics that describes older individuals with limited physiologic reserve who are at significant risk for adverse outcomes, including falls, disability, hospitalization, and death. An increasingly accepted definition of frailty is a syndrome in which ≥3 of the following are present: unintentional (lean) weight loss ≥10 pounds in the past year, weakness (measured by grip strength), slow walking speed, self‐reported exhaustion, and low physical activity. This clinical syndrome overlaps closely with the known toxicities of ADT. In addition, alterations in the inflammatory system, neuroendocrine system, and energy production are associated with this syndrome, as evidenced by biomarkers such as C‐reactive protein, interleukin‐6, and tumor necrosis factor‐α. For this article, the authors reviewed the evidence for the effect of ADT on each of the 5 frailty components plus the identified biomarkers, and the evidence indicates that ADT may accelerate the development of frailty in vulnerable older men with prostate cancer. Given the association of frailty with important clinical outcomes such as hospitalization and death, this potential consequence of ADT should be considered carefully when initiating therapy in older patients with recurrent prostate cancer. Cancer 2007. © 2007 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.23084

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 131

Metadata

Authors
Bylow, K., Mohile, S. G., Stadler, W. M., & Dale, W.
Venue
Cancer
Publisher
Wiley
Published
2007-10-24
Volume
110
Issue
12
Pages
2604-2613
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2007110777
Cited by
131
References
22
FWCI
4.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Does androgen‐deprivation therapy accelerate the development of frailty in older men with prostate cancer?: A conceptual review. https://app.cochat.ai/papers/10.1002/cncr.23084
The paper
Bylow, K., Mohile, S. G., Stadler, W. M., & Dale, W. (2007). Does androgen‐deprivation therapy accelerate the development of frailty in older men with prostate cancer?: A conceptual review. Cancer. https://doi.org/10.1002/cncr.23084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.